Search for Clinical Trial Results

Sponsored By

Exostoses, Multiple Hereditary - 7 Studies Found

Status Study
Completed Study Name: Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))
Condition: Multiple Myeloma
Date: 2005-05-25
Interventions:
  • Drug: vorinostat Vorinostat ca
Completed Study Name: Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)
Condition: Lymphoma
Date: 2008-10-09
Interventions: Drug: vorinostat Parts I & II: Vorinostat (400 mg) Oral, daily (QD). Treatment period is 28 days per
Completed Study Name: Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001 EXT1)(COMPLETED)
Condition: Pneumococcal Vaccines
Date: 2010-10-04
Interventions:
  • Biological: Adults-Adjuvanted V114

Completed Study Name: Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)
Condition:
  • Leukemia, Myelocytic, Acute Myelodysplastic Syndromes
  • Myelodysplastic Syndromes

Date: 2007-05-24
Interventions:
  • Drug: vorinostat Other Names:
Completed Study Name: An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))
Condition: Proteinuria
Date: 2007-12-03
Interventions:
  • Drug: Losartan Potassium

Terminated Study Name: Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)
Condition: Diabetes Mellitus, Type 2
Date: 2008-10-03
Interventions:
  • Drug: MK-0941 MK-0941 tablets

Completed Study Name: Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1)
Condition:
  • Mesothelioma
  • Lung Cancer

Date: 2005-08-05
Interventions:
  • Drug: vorinostat Vorinostat th